CDX-301 is under clinical development by Celldex Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CDX-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CDX-301 is under development for the treatment of low-grade B-cell lymphomas, pancreatic ductal adenocarcinoma, marginal zone lymphoma, follicular lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, non-small cell lung cancer, metastatic or unresectable triple negative breast cancer, small lymphocytic lymphoma and head and neck squamous cell carcinoma. The drug candidate is a recombinant FMS-like tyrosine kinase 3 ligand, or Flt3L is a hematopoietic cytokine administered subcutaneously and intratumorally. It acts by targeting receptor-type tyrosine-protein kinase FLT3. CDX-301 is a soluble, recombinant human Fms-like tyrosine kinase-3 ligand (Flt3L). It was also under development for the treatment of autoimmune diseases and HSC (hematopoietic stem cell) transplantation, mucosal melanoma or ocular melanoma and malignant melanoma.
For a complete picture of CDX-301’s drug-specific PTSR and LoA scores, buy the report here.